Compare REGCP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REGCP | IMNM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | 507 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.6B |
| IPO Year | N/A | 2020 |
| Metric | REGCP | IMNM |
|---|---|---|
| Price | $23.45 | $22.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 5.5K | ★ 900.7K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.35 | $7.96 |
| 52 Week High | $24.74 | $27.65 |
| Indicator | REGCP | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 49.13 |
| Support Level | $23.27 | $19.28 |
| Resistance Level | $23.51 | $23.25 |
| Average True Range (ATR) | 0.11 | 1.22 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 68.97 | 56.39 |
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.